CD8A and neoplasm: Indeed, in human clinical case studies, it was reported that tumor regression may be dependent on CD8+ T cells directed against tumor antigens not present in the vaccine, and thus, the induction of CD8+ T cells might be a suitable surrogate biomarker based on immune‐related response criteria to evaluate therapeutic vaccines.121